Update on B-Cell Leukemias and Lymphomas

Dear Colleagues,

We are witnessing recent advancements in personalized treatments and innovative therapies for hematological malignancies. Genomic profiling helps identify mutations linked to B-cell leukemias and lymphomas and other clonal cell blood populations, enhancing risk assessment and tailoring treatments. Innovative approaches like CAR T-cell therapy have demonstrated significant effectiveness, especially in cases that are relapsed or refractory. Additionally, research into the tumor microenvironment highlights its critical influence on disease progression and treatment response. New biomarkers are being studied to improve diagnostic precision and track treatment effectiveness. We are interested in articles that are looking into resistance mechanisms, such as mutations in B-cell receptor signaling pathways, with the goal of developing combination therapies that could overcome therapeutic challenges. Moreover, understanding the clonal evolution of B-cell malignancies is leading to the emergence of new treatment strategies.

This Special Issue will cover genomic alterations, the most frequent mutations and tumor markers, improved risk assessment, B-cell receptor signaling pathways, tumor microenvironment highlights involved in cancer advancement and recurrence. Reviews and research articles are both welcomed on the following topics:

• Lymphoid-related mutations and translocations that initiate and drive tumor formation of lymphomas.
• Genomic mutations and alterations in B-cell receptor signaling pathways which promote tumor growth and metastasis.
• Genomic biomarkers that forecast blood cell malignancy recurrence.
• The use of genomic data for tailored CAR T therapies and specific treatment approaches.
• Bone marrow microenvironment, friend or foe, in hematological malignancies.

Dr. Diana Cenariu
Dr. Adrian-Bogdan Țigu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biomarkers for diagnosis
• genetic mutations
• epigenetic regulation
• niche interaction
• immunotherapy
• targeted therapy
• CAR T-cell therapy